Takeda Pharmaceutical Co ADR [TAK] stock is trading at $13.11, down -1.87%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TAK shares have lost -3.32% over the last week, with a monthly amount drifted -3.10%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Takeda Pharmaceutical Co ADR [NYSE: TAK] stock has seen the most recent analyst activity on March 16, 2023, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, Cowen upgraded its rating to Outperform on July 19, 2022, and elevated its price target to $24. On October 07, 2021, downgrade downgraded it’s rating to Equal-Weight. JP Morgan downgraded its rating to a Neutral. Cowen initiated its recommendation with a Market Perform and recommended $19.50 as its price target on November 01, 2019. Daiwa Securities downgraded its rating to Neutral for this stock on August 15, 2019.
Takeda Pharmaceutical Co ADR [TAK] stock has fluctuated between $12.57 and $15.08 over the past year. Takeda Pharmaceutical Co ADR [NYSE: TAK] shares were valued at $13.11 at the most recent close of the market.
Analyzing the TAK fundamentals
Takeda Pharmaceutical Co ADR [NYSE:TAK] reported sales of 30.22B for the trailing twelve months, which represents a growth of 9.21%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.02 points at the first support level, and at 12.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.28, and for the 2nd resistance point, it is at 13.46.
Ratios To Look Out For
For context, Takeda Pharmaceutical Co ADR’s Current Ratio is 1.28. Further, the Quick Ratio stands at 0.77, while the Cash Ratio is 0.36. Considering the valuation of this stock, the price to sales ratio is 1.38, the price to book ratio is 0.86 and price to earnings (TTM) ratio is 21.74.
Transactions by insiders
Recent insider trading involved Giles Richard Platford, President, Plasma-Derived Ther, that happened on Aug 23 ’24 when 19073.0 shares were purchased. 10% Owner, TAKEDA PHARMACEUTICAL CO LTD completed a deal on Jan 24 ’24 to sell 3.7 million shares.
